Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.62 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | MPO | P05164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30866618 | 1.00 | TAAR1 (0.62) | TAAR1AOC3IDO1MPOMEN1 | |
| Ammonia Solution, Strong SCHEMBL6195354 | 0.98 | TAAR1 (0.60) | TAAR1AOC3IDO1MPOMEN1 | |
| Ethyne SCHEMBL27645780 | 0.95 | TAAR1 (0.58) | TAAR1AOC3IDO1MPOMEN1 | |
| SCHEMBL1073302 | 0.86 | TAAR1 (0.58) | TAAR1AOC3IDO1MPO | |
| SCHEMBL14402410 | 0.84 | TAAR1 (0.56) | TAAR1AOC3MPOMEN1KMT2A | |
| SCHEMBL8526001 | 0.84 | TAAR1 (0.75) | TAAR1AOC3IDO1MPOLMNA | |
| SCHEMBL19540031 | 0.82 | LIPG (0.58) | TAAR1AOC3MPOMEN1KMT2A | |
| SCHEMBL2241863 | 0.82 | LIPG (0.58) | TAAR1AOC3MPOMEN1KMT2A | |
| SCHEMBL19540033 | 0.82 | LIPG (0.58) | TAAR1AOC3MPOMEN1KMT2A | |
| SCHEMBL2584935 | 0.82 | LIPG (0.58) | TAAR1AOC3MPOMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1234460-C | Regeneration process for solid acid catalyst | CHINA PETROCHEMICAL CROP (CN) | 2006-01-04 | — | — | CN | claimed |
| CN-1234459-C | Application method of solid acid catalyst | CHINA PETROCHEMICAL CORP (CN) | 2006-01-04 | — | — | CN | claimed |
| CN-1541768-A | Application method of solid acid catalyst | 中国石油化工股份有限公司 | 2004-11-03 | — | — | CN | claimed |
| CN-1520928-A | Regeneration process for solid acid catalyst | 中国石油化工股份有限公司 | 2004-08-18 | — | — | CN | claimed |
| WO-2023240253-A2 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023235548-A1 | SQUARAMIDE DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230322765-A1 | COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| WO-2023187182-A1 | PYRAZOLOPYRAZINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2023-10-05 | — | — | WO | disclosed |
| US-11724997-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | ANNAPURNA BIO, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230242508-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| EP-3423429-B1 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | UNIV DE MONCTON (CA) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023115142-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
| EP-1334976-A1 | Novel phosphine compound, transition metal complex containing said compound as ligand and asymetric synthesis catalyst containing said complex | Takasago International Corporation (JP) | 2003-08-13 | — | — | EP | disclosed |
| WO-1998043649-A2 | AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
| US-5703017-A | HERBICIDES, PLANT GROWTH REGULATORS | BASF AKTIENGESELLSCHAFT (DE) | 1997-12-30 | — | — | US | disclosed |
| CN-1034864-C | Maillard reaction inhibitor | OTSUKA PHARMA CO LTD (JP) | 1997-05-14 | — | — | CN | disclosed |
| US-5422360-A | Hydrazonoimidazolidin-4-one derivatives; treatment of diabetes and aging disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-06 | — | — | US | disclosed |
| EP-0531812-A1 | Maillard reaction inhibitor, process for producing it, composition containing it and the use thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
| CN-1069728-A | Maillard reaction inhibitor | OTSUKA PHARMA CO LTD (JP) | 1993-03-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11724997-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | APLNR, AGTR1, AGTR2 | TAAR1 1160/4885AOC3 4082/4885IDO1 3768/4885 |
| US-20230322765-A1 | COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH | PC, FH, PDK1 | TAAR1 3378/4885AOC3 1664/4885IDO1 1180/4885 |
| US-20230242508-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | TAAR1 4838/4885AOC3 2829/4885IDO1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.